Is GRI Bio Inc. (GRI) overvalued? · P/E 0.1, $3.5M cap
GRI Bio Inc. (GRI) is a biotechnology company listed on US.
This page asks whether GRI Bio Inc. (GRI) looks expensive on cached numbers — not a short thesis.
No cached income statement for GRI, so there is no earnings base to call rich or cheap.
GRI currently screens at market cap $3.5M and trailing P/E 0.1. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next GRI 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the GRI stock page for the full model, not this heading.
Not investment advice.